Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Código QR

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1 Hassan Al-Dhibi,1 Abdulelah A Al-Abdullah1 1King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; 2King Abdullah Medical City, Makkah, Saudi Arabia; 3College of Medicine, King Saud University, R...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	aflibercept bevacizumab persistent dme ranibizumab vegf switch vascular endothelial growth factor Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6c17e55774c24a50b1c2e43f1d1e0882
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti D, et al.
Publicado: (2021)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
por: Dirani A, et al.
Publicado: (2018)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi Y, et al.
Publicado: (2017)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
por: Kiss S, et al.
Publicado: (2018)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)

Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
por: Rodolfo Mastropasqua, et al.
Publicado: (2018)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
por: Tagami M, et al.
Publicado: (2017)

Immediate sequential bilateral intravitreal injections: an Indian perspective
por: Tripathy K
Publicado: (2017)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
por: Lin CJ, et al.
Publicado: (2016)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
por: Shakarchi FI, et al.
Publicado: (2018)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan R, et al.
Publicado: (2016)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran THC, et al.
Publicado: (2021)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
por: Jumper JM, et al.
Publicado: (2018)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
por: Jang K, et al.
Publicado: (2020)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Jia-Kang Wang, et al.
Publicado: (2018)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
por: Korol AR, et al.
Publicado: (2017)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
por: Laine I, et al.
Publicado: (2017)

Update on corticosteroids for diabetic macular edema
por: Schwartz SG, et al.
Publicado: (2016)

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
por: Ehlken C, et al.
Publicado: (2017)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
por: Liu J, et al.
Publicado: (2019)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Dimitrios A Karagiannis, et al.
Publicado: (2009)

Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
por: Singer M, et al.
Publicado: (2020)

Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy
por: Tsubota K, et al.
Publicado: (2019)

Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
por: David Blánquez-Martínez, et al.
Publicado: (2021)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim LS, et al.
Publicado: (2015)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose R, et al.
Publicado: (2016)